These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
296 related articles for article (PubMed ID: 38273744)
1. Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go? Singh V; Ulasov I; Gupta S; Singh A; Roy VK; Kharwar RK Discov Med; 2024 Jan; 36(180):22-47. PubMed ID: 38273744 [TBL] [Abstract][Full Text] [Related]
2. The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis. Aiello M; Bertorelli G; Bocchino M; Chetta A; Fiore-Donati A; Fois A; Marinari S; Oggionni T; Polla B; Rosi E; Stanziola A; Varone F; Sanduzzi A Pulm Pharmacol Ther; 2017 Jun; 44():7-15. PubMed ID: 28257817 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203 [TBL] [Abstract][Full Text] [Related]
4. Nintedanib for the treatment of idiopathic pulmonary fibrosis. Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616 [TBL] [Abstract][Full Text] [Related]
6. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib. Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic targets in idiopathic pulmonary fibrosis. Kolb M; Bonella F; Wollin L Respir Med; 2017 Oct; 131():49-57. PubMed ID: 28947042 [TBL] [Abstract][Full Text] [Related]
8. Inflammation and immunity in IPF pathogenesis and treatment. Heukels P; Moor CC; von der Thüsen JH; Wijsenbeek MS; Kool M Respir Med; 2019 Feb; 147():79-91. PubMed ID: 30704705 [TBL] [Abstract][Full Text] [Related]
9. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. Moodley Y; Corte T; Richeldi L; King TE Respirology; 2015 Apr; 20(3):389-94. PubMed ID: 25727967 [TBL] [Abstract][Full Text] [Related]
13. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients. Feng H; Zhao Y; Li Z; Kang J Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705 [TBL] [Abstract][Full Text] [Related]
14. Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension. Hadi DD; Marsool MDM; Marsool ADM; Vora N; Al-Badri SG; Al-Fatlawi NHK; Abbas Al Wssawi AF; Al-Ibraheem AMT; Hamza KA; Prajjwal P; Mateen MA; Amir O Immun Inflamm Dis; 2023 Nov; 11(11):e1079. PubMed ID: 38018591 [TBL] [Abstract][Full Text] [Related]
15. ATP-induced fibrogenic pathway in circulating cells obtained by idiopathic pulmonary fibrotic (IPF) patients is not blocked by nintedanib and pirfenidone. Colarusso C; Falanga A; Di Caprio S; Terlizzi M; D'Andria E; Antonio M; Maiolino P; Sorrentino R Biomed Pharmacother; 2024 Jul; 176():116896. PubMed ID: 38876049 [TBL] [Abstract][Full Text] [Related]